#MarksManInsights

Within the broader spectrum of healthcare, women represent a significant and distinct demographic with unique health needs and outcomes, underscoring the importance of focused research in this domain. The realm of women’s health research is vast and vital, addressing conditions and diseases that predominantly or exclusively affect women, such as reproductive health issues, breast and cervical cancers, and osteoporosis. Women’s health research also sheds light on how common conditions like cardiovascular diseases and autoimmune disorders present and progress differently in women compared to men. Another compelling reason to prioritize women’s health research is the significant physiological and hormonal distinctions between women and men, which can profoundly influence disease manifestation, progression, and treatment response. For example, cardiovascular disease, the leading cause of death among women globally, often exhibits atypical symptoms in women, such as fatigue and shortness of breath, rather than the classic chest pain.[1]

However, traditional research methods often overlook these gender differences. For instance, randomized controlled trials (RCTs) often exclude pregnant women: even though such an exclusion is justified from the foetal viewpoint, such exclusions bring in inadequacy in women’s health research. Such inadequacies highlight the necessity for gathering research insights from real-world data (RWD), thereby complementing evidence from controlled settings. Thus, outcomes research and real-world evidence (RWE) becomes an important source of research information for women’s health.[2]

Outcomes research and RWE play a pivotal role in addressing health disparities among women, particularly in maternal care. Preapproval clinical trials typically exclude pregnant women, necessitating reliance on post-approval controlled observational studies to gather evidence on pregnancy safety essential for drug labels. Regulatory agencies increasingly recommend complementing pregnancy registries and case-control studies with pregnancy cohorts nested within healthcare utilization databases, such as national registries, electronic medical records (e.g., Clinical Practice Research Datalink), and insurance claims. The utilization of RWE has uncovered significant disparities in maternal health outcomes, fostering health equity and improving overall outcomes for women.[3-7]

In cancer care, RWE has been instrumental in advancing treatment strategies for women. Breast cancer, the most common cancer among women, has benefited significantly from real-world studies. RWE has been known to support clinical guidelines by providing data on specific subgroups of patients not well-represented in RCTs. For example, in early-relapsing HER2+ advanced breast cancer, RWE has provided valuable insights into treatment outcomes, helping to guide clinical decision-making and refine treatment protocols. Subsequently, RWE and outcomes research have facilitated a deeper understanding of the real-world efficacy of hormone therapies and the impact of different chemotherapy regimens on diverse patient populations. This has led to more personalized treatment plans that consider the unique needs of each patient, fostering improved communication between physicians and patients and enhancing overall care and outcomes for women with breast cancer.[7-9]

Another critical facet of women’s health research involves the inclusion of all age groups, from adolescence to post-menopause, each life stage presenting unique health challenges. RWE serves as a cornerstone in shaping interventions tailored to these diverse needs. For instance, a 2022 study revealed the influence of social media on the mental health of young girls, emphasizing the need for interventions promoting positive body image. Conversely, for older women, real-world data has yielded insights into treatment effectiveness and patient-reported outcomes, guiding healthcare strategies to address age-specific health concerns.[9-12]

In conclusion, the outcomes research and RWE are indispensable for advancing women’s health. By illuminating the intricacies of disease presentation, treatment outcomes, and healthcare disparities, these methodologies empower healthcare practitioners to deliver more personalized, effective, and equitable care to women across diverse demographics and life stages. From addressing cardiovascular disease manifestations to improving maternal care and refining breast cancer treatment strategies, outcomes research and RWE play a pivotal role in ensuring that healthcare solutions are truly reflective of and responsive to the needs of all women, from adolescence to post-menopause. Through these approaches, we continue to break barriers, promote health equity, and enhance the quality of care for women worldwide.

Become A Certified HEOR Professional – Enrol yourself here!

References:

1. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence—what is it and what can it tell us. 2016 Dec 8;375(23):2293-7.
2. Siristatidis C, Karageorgiou V, Vogiatzi P. Current Issues on Research Conducted to Improve Women’s Health. Healthcare (Basel). 2021 Jan 17;9(1):92. doi: 10.3390/healthcare9010092.
3. Why we know so little about women’s health. Available from: https://www.aamc.org/news/why-we-know-so-little-about-women-s-health.
4. Heyrana K, Byers HM, Stratton P. Increasing the participation of pregnant women in clinical trials. Jama. 2018 Nov 27;320(20):2077-8.
5. Gliklich RE, Dreyer NA, Leavy MB, editors. Registries for evaluating patient outcomes: a user’s guide.
6. Food and Drug Administration. Guidance for industry: establishing pregnancy exposure registries. Washington, DC: US Department of Health and Human Services. Available from: https://www.fda.gov/media/75607
7. Mitchell AA. Systematic identification of drugs that cause birth defects—a new opportunity. New England Journal of Medicine. 2003 Dec 25;349(26):2556-9.
8. Huybrechts KF, Bateman BT, Hernández‐Díaz S. Use of real‐world evidence from healthcare utilization data to evaluate drug safety during pregnancy. Pharmacoepidemiology and drug safety. 2019 Jul;28(7):906-22.
9. Schettini F, Conte B, Buono G, et al. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. ESMO open. 2021 Apr 1;6(2):100099.
10. DuBenske LL, Schrager SB, Hitchcock ME, et alKey elements of mammography shared decision-making: a scoping review of the literature. Journal of General Internal Medicine. 2018 Oct;33:1805-14.
11. Papageorgiou A, Fisher C, Cross D. Why don’t I look like her? How adolescent girls view social media and its connection to body image. BMC women’s health. 2022 Jun 27;22(1):261.
12. Maruszczyk K, Aiyegbusi OL, Torlinska B, et al. Systematic review of guidance for the collection and use of patient-reported outcomes in real-world evidence generation to support regulation, reimbursement and health policy. Journal of Patient-Reported Outcomes. 2022 Jun 2;6(1):57.